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Abstract Prolongedcoughis a commonprobleminpatients seeningeneralpractice.Usinga simplemethodof sputum
induction andprocessingof sputum samples, we determinedwhethereosinophilic airwayin£ammation couldbe a cause
of undiagnosed prolonged cough.Eighty-two patientswho had had cough formore than1monthwere enrolled into the
study, in sixprimaryhealthcare centres.Patientswithknownpulmonarydisease, includingasthmaorchronicobstructive
pulmonary disease (COPD), or who were known to have another cause of cough, or to have recently su¡ered from a
respiratoryinfection, were excluded.Fifty-threehealthyindividuals servedas controls.Sputumwasinducedbyinhalation
of 3% saline.In£ammatorycells in smearswere studied semi-quantitatively.Concentrations of eosinophil cationic protein
(ECP), eosinophilperoxidase (EPO), myeloperoxidase (MPO) andhumanneutrophilic lipocalin (HNL) were determined.
Sputuminductionproved safe and adequate sampleswere obtained from 91%.Sputumeosinophilia (eosinophils account-
ing formore than 5% of all cells in smears) waspresent in14 patientswith prolonged cough (19%) but inno healthy indivi-
dual (P=0?001).Five ofthe14 individuals (36%)who exhibited sputumeosinophilia appearedtohave asthma,whilenine of
the14 (64%) did not.Concentrations of ECP and EPO were higher in patients with prolonged cough than in healthy in-
dividuals (P=0?02 for ECP; 0?005 for EPO).Weconcludethateosinophilic airwayin£ammationis a fairlycommoncause of
prolonged cough, even in patients not su¡ering fromasthma or COPD, or inwhomno other cause of cough is knownto
be present.Induced sputum samples obtained in health centres can be studied in a central laboratory.Detection of eosi-
nophilic airwayin£ammation could aid the decisionregarding treatment.r2002 Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1215, available online athttp://www.idealibrary.comon
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Prolonged cough is a common problem in patients seen
in primary healthcare.Cough can indicate the existence
of or precede the occurrence of asthma.Variable airway
obstruction, demonstration of which is the traditional
basis for a diagnosis of asthma, is usually associatedwith
chronic eosinophilic in£ammation of airway mucosa (1).
The existence of such in£ammation cannot readily be di-
agnosed inprimaryhealth carebecause of lackof suitable
methods.Received 6November 2000 and accepted in revised form19 September
2001.
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@hus.¢It has been estimated that within the Finnish National
Asthma Programme (2), as many as 10% of the popula-
tion, apart from asthma patients, occasionally exhibits
symptoms suggesting that they are su¡ering from mild
asthma, even though results of lung-function tests are
normal or close to normal. Many such patients may be
exhibiting eosinophilic airway in£ammation, the main
pathophysiological characteristic of asthma (3^6). Since
diagnosis and treatment of asthma is based on demon-
stration of pulmonary dysfunction, patients of this
kind, in whom diagnosis can be ambiguous, may not
receive appropriate medication. It has recently been
suggested that the term ‘asthma-like in£ammation’
or ‘eosinophilic bronchitis’ should be employed to
describe the disorder from which such patients are
su¡ering (7,8).
The importance of early initiation of anti-in£amma-
tory treatment if a good response to treatment is to be
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chronic has been emphasized (9,10).Means of con¢rming
the existence of asthma or asthmatic in£ammation in
cases inwhich there is no regular pulmonary dysfunction
is therefore desirable. Patients with chronic obstructive
pulmonary disease (COPD) who exhibit eosinophilic air-
way in£ammation may bene¢t from anti-in£ammatory
therapy (11). The same is true of patients with isolated
chronic cough and sputum eosinophilia (5,12). A simple
method for detection of eosinophilic airway in£amma-
tionwould therefore be valuable.
Over the past 10 years sputum induction has been
found to be a relatively non-invasive way in which the
nature and degree of airway in£ammation in asthma
and other airway diseases can be assessed. Results of
sputum analysis may re£ect in£ammatory processes af-
fecting airway mucosa more accurately than results of
blood and serum measurements (13). Methods for spu-
tum induction have developed and have been shown to
bereproducible andvalid (14,15).Theyhavehoweverbeen
used only in hospitals.We have described a simplemeth-
od for sputum induction and processing of samples, and
have shown this to be valid (16). It can be used in primary
health care.
In the study presented here the method was used to
assess the nature and degree of eosinophilic airway in-
£ammation in patients with prolonged cough seen in pri-
mary health care.
METHODS
Subjects
Eighty-two consecutive patients not known to be su¡er-
ing fromasthma or anyother chronic respiratorydisease
were enrolled into the study, in six health-care centres in
the Helsinki area of Finland, between November 1997
February1998, i.e. outside thepollen season.Each centre
serves a population of some 30 000.Patients complaining
that they had been coughing daily formore than1month
were eligible for enrolmentinto the study.Patientshad to
be symptomatic at the time of study. They were ques-
tioned carefully about respiratory symptoms other than
cough. Patients being treated with anti-in£ammatory
asthmamedication (corticosteroids, disodiumcromogly-
cate, nedocromil sodium, theophylline, leukotriene an-
tagonists) or using ACE inhibitors were excluded.
Patients who had su¡ered from a respiratory infection
during the preceding 6 weeks or who exhibited symp-
toms of rhinitis or gastro-oesophageal re£ux were also
excluded. Patients had to have normal chest and sinus X-
rays results, and normal serum C-reactive protein va-
lues.Fifty-three healthy control subjects with no history
of asthma or other respiratory symptoms were re-
cruited from the sta¡ of the Skin and Allergy Hospital,
Helsinki University Central Hospital.The study had been approved by the Ethics Commit-
tees of the Skin andAllergyHospital, and thehealth care
centres. All subjects gave their informed consent topati-
cipation in the study.
Clinicalmethods
Health centre physicianswere asked to complete a ques-
tionnaire regarding the symptoms andmedical history of
each patient. Participants were subjected to careful phy-
sical examination, including auscultation of their lung
sounds. Peak expiratory £ow (PEF) values (the highest
values of three successful attempts) (Mini Wright Peak-
Flow Meter, Clement Clarke International, London,
U.K.) were recorded for all patients and controls. If the
physician suspected asthma on the basis of the results,
the variability of PEF valuesmeasuredmornings and eve-
nings over a 2-weekperiodwasrecorded.When feasible,
lung volumes weremeasured, using dynamic spirometry
(Vitalograph, Spirotrac III, Buckingham, U.K.) in accor-
dancewith standardmethods (17).Reversibility in forced
expiratory volume in 1sec (FEV1) was assessed 15min
after inhalation of 200mg of salbutamol (Buventol Easy-
halers100mgdoseÿ1,Orion Pharma, Espoo, Finland).
Skinprick testswere conductedusing11commoninha-
lant allergens (Soluprick SQ,10HEP,ALK,Denmark), and
positive (histamine dihydrochloride, 10mgmlÿ1) and ne-
gative (solvent) control solutions. A subject was classi-
¢ed as atopic if any allergen caused a weal of 3mm or
more in diameter and control solution gave expected re-
sults (18).
Blood samples were taken by venipuncture. Serum
was separated under standardized conditions, according
to the instructions of the manufacturer (Pharmacia &
Upjohn Diagnostics, Uppsala, Sweden), permitting re-
lease of leukocyte activationmarkers.
Sputum induction
Sputumwas inducedby inhalation of 5ml of 3%NaCl so-
lution, using an ultrasonic nebulizer (Omron U1,Omron,
Germany) for 15min. Subjects were pre-treated with
200mg salbutamol (Buventol Easyhalers 100mg doseÿ1),
by inhalation.PEF valuesweremeasuredbefore and after
induction, to ensure safety of the procedure. Subjects
were asked to cough during and after inhalation. Sputum
sampleswere collected in empty containers. If PEF fell by
more than15% or troublesome symptoms appeared, pa-
tients were treatedwith 200mg of inhaled salbutamol.
Sputumsample handling in primary health
care
Sputum sampleswere transferred to Petri dishes and ex-
amined against a dark surface. The more viscous parts
54 RESPIRATORYMEDICINEwere collected, using forceps, and mixed (14). Part of
each sample was used to make two smears, which were
air-dried (not frozen).The rest of each samplewas trans-
ferred into a pre-weighed tube and frozen atÿ201C.
Sputumanalysis in the laboratory
Frozen sputum samples and the air-dried slides were
sent to the Skin andAllergyHospital,where further ana-
lyses were undertaken. Samples were processed using a
method previously described and validated (16). Brie£y,
each sample was thawed and treated with a mucolytic
agent (SputolysinTM,CalbioChem,La Jolla,U.S.A., diluted
10-fold with distilledwater) and a detergent (0.5% cetyl-
N,N,N,-trimethylammonium bromide, 0.4% human ser-
um albumin, 100mM phosphate-bu¡ered saline, pH 7?2).
After incubation for1h, cells were lysed andmarkers in-
side and outside the cells released and solubilized. The
sputum supernatant was separated from cell debris by
centrifugation. Thawed sputum supernatant concentra-
tions (mglÿ1) of two eosinophil- activationmarkers, eosi-
nophil cationic protein (ECP) and eosinophil peroxidase
(EPO), and of twomarkers of neutrophil activation,mye-
loperoxidase (MPO) and human neutrophil lipocalin
(HNL) were determined. ECP and MPO concentrations
were determined using commercially available immu-
noassay kits (Pharmacia & Upjohn Diagnostics), and
EPO and HNL concentrations using prototype kits
(Pharmacia CAP System FEIA, Pharmacia & Upjohn
Diagnostics) as previously described (19). In serum sam-
ples only ECP wasmeasured.
The air-dried slides were stained using eosin and
methylene blue. Cell proportions were assessed semi-
quantitatively, on a scale from 0 to 4, modi¢ed from pre-
viouslydescribed scales (20).Eosinophiliawas gradedas 0
(no or occasional eosinophils),1 (scanty), 2 (moderate), 3
(numerous eosinophils), or 4 (predominance of eosino-
phils). Approximately, grade 0 corresponded to eosino-
phils accounting for fewer than 1% of all non-squamous
cells, grade 1 to eosinophils accounting for one to 5% of
all non-squamous cells, grade 2 to eosinophils accounting
for 5^10% of all non-squamous cells, grade 3 to
eosinophils accounting for 10^50% of all non-squamous
cells and grade 4 to eosinophils accounting for more
than 50% of all non-squamous cells. A sample was
considered to be adequate, and to originate from the
lower airways, if it contained macrophages and fewer
than 50% of squamous epithelial cells. All analyses were
conducted unaware of the clinical characteristics of the
subject.
Data analysis
Data are expressed as means or medians and ranges.
Some values for in£ammatory markers lay beneath thelowest standard values. Signi¢cances of di¡erences be-
tween two groups were determined using the Mann^
Whitney U-test or the w2-test, as appropriate. Signi¢-
cances of correlationswere determinedusing Spearman’s
rank correlation test. A P-value below 0?05 in a two-
tailed test was considered to indicate signi¢cance. The
control group was used to establish upper limits of the
normal ranges (90th percentiles) for sputum ECP, EPO,
MPO and HNL values.
RESULTS
Clinical characteristics
The clinical characteristics of subjects are shown inTable
1. PEF values were normal in all healthy controls. In the
patients su¡ering from prolonged cough, PEF values var-
ied from47 to136%of thepredictedvalue (21).Two-week
PEF follow-up values were obtained for 41 of the 82
cough patients (50%) and spirometry results for 31 pa-
tients (38%).On the basis of PEF values varying by more
than 20% between morning and evening over 3 days of
the 2-week follow-up period, or a reversibility of more
than15% in FEV1,13 of the 82 cough patients (16%) were
diagnosed as su¡ering from asthma (22).None of the 23
cough patients who smokedmet the criteria for chronic
bronchitis or COPD (22).
Mean duration of cough was 11 months (range 1^96
months); it was15 months for asthmatics,10 months for
the other patients. Forty cough patients (49%) reported
marked sputum production, 38 (46%) wheezing or
coughing on exercise, 30 (37%) disturbed sleep, 28 (34%)
shortness of breath, and 23 (28%) tightness of the chest
withwheezing. Asthmatics experienced sputumproduc-
tion (P=0?03, w2-test) and tightness of the chest with
wheezing (P=0?04, w2-test) more often than patients
with prolonged cough not meeting the criteria for asth-
ma.
Sputum induction
Sputum inductionwas found to be safe.Themean change
in PEF during sputum induction was ÿ1?4% (range ÿ13^
32%) from baseline (Table 1). No subject required treat-
ment with a bronchodilator following sputum induction.
An adequate sputum sample was obtained from 73 pa-
tients (89%) and 49 healthy controls (92%) (Table1).
Eosinophils and in£ammatorymarkers
Results of serum and induced sputummeasurements are
shown in Table 2. Serum ECP levels were signi¢cantly
higher in patients with prolonged cough than in healthy
controls (P=0?01). Scores for sputum eosinophils were
higher in patients with prolonged cough than in controls
(P=0?001). No healthy control had a score for sputum
TABLE 1 Characteristics of subjects
Characteristics Prolonged cough
(n=82)
Healthycontrols
(n=53)
Ageyears 46 (16^85) 42 (25^61)
Male/female 25/57 10/43
Atopic* 12 (15%) 9 (17%)
Smokers 23 (28%) 3 (6%)
FEV1 (% of predicted)
w 82 (41^111) Notdetermined
PEF (% of predicted) 91 (47^136) 103 (87^120)
PEF-variability (%)z 13 (0^30) Notdetermined
Duration of cough (month) 11 (1^96)
Change in PEF during induction (%) ÿ1?1 (ÿ13^32) ÿ3?0 (ÿ17^19)
Adequate sputum sample} 73 (89%) 49 (92%)
Data are expressed asmeans andranges ornumbers andpercentages of patients.
*De¢ned as at leastone positive result in allergy skin-prick testing (seemethods).
wn=30 (21).
zPeak expiratory £ow variability between morning and evening, n=41 (three values showing greatest variability between
morningand eveningaveraged over 2-week follow-up period).
}De¢ned as a sample containingmacrophages and fewer than 50% of squamous epithelial cells.
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sample was de¢ned as eosinophil-positive if the sputum
eosinophil scorewas 2, 3 or 4.Using this criterion,14 pa-
tients with prolonged cough (19%) had eosinophil-posi-
tive sputum samples. Five of these 14 patients (36%)
were diagnosed as having asthma, while nine of the 14
patients (64%) were not.On the other hand, eosinophils
were found in the sputum of ¢ve patients (45%) who
were diagnosed as having asthma, and in nine patients
with prolonged coughwithout asthma (15%).
EPO and ECP levels in sputum samples were higher in
patients with prolonged cough than in healthy controls
(Table 2). Values for the markers of neutrophils in spu-
tum,MPO and HNL, did not di¡er signi¢cantly between
patients with prolonged cough and controls. There
were no signi¢cant di¡erences in in£ammatory markers
between smokers and non-smokers, or between
atopic and non-atopic subjects in any group. When
smokers were excluded from analysis di¡erences were
similar.
In the healthy controls, the upper reference limit for
ECP in serum was 16.5mglÿ1, for ECP in sputum
1987mg lÿ1, for EPO in sputum 3899mglÿ1, for MPO in
sputum 1012mglÿ1, and for HNL in sputum 14286mglÿ1.
Percentages of subjects with values above reference
levels are shown in Fig.1.
DISCUSSION
The importance of measuring airway in£ammation in
chronic respiratory conditions such as asthma, COPDand prolonged cough has recently been emphasized
(23). Airway in£ammationcanbereadily studiedusing in-
duced sputum samples.Results of such studies have been
shown to be reproducible, and similar to those obtained
through employment of more invasive bronchoscopic
methods (13,14, 24).However, the studies havebeen con-
ducted only in hospitals. Sample processing has been la-
borious. We modi¢ed the study method by simplifying
sample processing, and showed that results were similar
to those obtained using the previously validated refer-
encemethod (16). In the study reportedhere, sputum in-
duction took place in ‘real-life situations’, in o⁄ce
practices where patients are ¢rst seen.
The success rate for adequate sputum sample was
high, 91%. Sputum induction was supervised by a trained
nurse. PEF-values were monitored before and after the
procedure. Inductionwas found to be safe. Since sputum
samples for determination of levels of in£ammatorymar-
kers can be frozen after collection (16), samples can be
taken in health centres and studied later, in central la-
boratories.
We found that 19% of the patients with prolonged
cough exhibited sputum eosinophilia (eosinophils ac-
counting for more than 5% of all cells in smears). Ap-
proximately two-thirds of those exhibiting sputum
eosinophilia were not diagnosed as su¡ering from asth-
ma. In studies in tertiary consultation clinics, non-asth-
matic eosinophilic in£ammation in patients with
prolonged cough has been found in lower percentages
of patients (4, 5). However, these studies included many
patients diagnosed as su¡ering from post-nasal drip or
gastro ^ oesophageal re£ux.
Table 2 Induced sputumand serummeasurements
Prolonged cough
(n=82)
Healthypersons
(n=53)
Sputum sample
Weight (mg) 290 (10-2980) 110 (3-913)
Eosinophils*
0-1 59 (81%) 49 (100%)
2 7 (10%) 0 (0%)
3 4 (5%) 0 (0%)
4 3 (4%) 0 (0%)
ECP (mglÿ1)w 1015 (44 - 65062) 498 (68 - 2706)
EPO (mglÿ1)z 297 (55 -33408) 63 (25 - 6830)
MPO (mglÿ1) 93 (80 -34300) 138 (80 - 1524)
HNL (mglÿ1) 7?3 (0.5 -98) 5?4 (1?1- 19)
Serum ECP (mglÿ1)} 10?5 (2 - 71) 6?7 (2 - 17)
Data are expressed as medians and ranges or numbers and percentages (in relation to eosinophils). Sputum samples were
obtained from 73 patients with prolonged cough and 49 healthy persons. Studied semi-quantitatively, on a scale from 0 to 4,
P=0?001 (w2-test).
wP=0?02.
zP=0?005.
}P=0?01Mann^Whitney U-test.
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FIG. 1. Percentagesofpatients andhealthypersonswithvalues
above reference values in serum or induced sputum analysis.
Prolonged cough and healthy persons. *P=0?01, wP=0?001,
zPo0?0001, }P=0?04 (w2-test).
56 RESPIRATORYMEDICINEIt has been estimated that more than 25% of any po-
pulationwithprolonged cough seekinghelp fromgeneral
practitioners will be su¡ering from asthma (25, 26). In
the studyreportedhere, on thebasis of results of clinical
examinations and lung function tests, 13 of the 82 pa-
tients with persistent cough (16%) were diagnosed for
the ¢rst time as su¡ering from asthma. However, sincePEF follow-up or spirometry were not done in 15 sub-
jects, the possibility cannot be excluded that some of
these subjects might have met the criteria for asthma
and that the incidence of asthma may therefore have
been slightly underestimated. Taken into account the
prevalence of asthma in the study population that had
lung function testing, we couldhavemissed two to three
subjectswith asthma.Lung functionwas however tested
in all patients with eosinophilic airway in£ammation. As
the study was carried out in patients attending for pri-
mary care, airway responsiveness could not be mea-
sured.
We aimed to exclude common causes of prolonged
cough, such as chronic rhinitis, sinusitis and post-nasal
drip, gastro ^ oesophageal re£ux and use of ACE inhibi-
tors.Other possible causes of prolonged cough, such as
lung parenchymal disease, were excluded on the basis of
chest X-ray ¢ndings and by careful interview of each pa-
tient. Airwayeosinophilia canoccur in otherwisehealthy
individuals during and after viral infection (27).We tried
to exclude the e¡ects of viral infection by including only
patients who had exhibited no signs of respiratory infec-
tion during the preceding 6 weeks.
General practitioners treat many patients with pro-
longed cough, sputumproduction and occasionalwheez-
ing but normal or close-to-normal lung function. The
in£ammatory process that could be associated with the
persistent respiratory symptoms is usually not charac-
terised. Clinical judgements are formed on the basis of
indirect information relating to bronchial status, such as
results of lung-function or allergy tests. Diagnosis of
EOSINOPHILICAIRWAYINFLAMMATIONINPRIMARYCARE 57early, mild asthma can be di⁄cult, since results of lung-
function tests can remain close to normal for long peri-
ods, or may be con£icting (28,29). In patients with
chronic cough whose lung function is normal it is only
by analysis of sputum samples that eosinophilic bronchi-
tis can be diagnosed (4, 5).
Thenatural courses of untreatedor under-treated eo-
sinophilic airway in£ammation are unknown (8).Many of
the patients concerned may never develop asthma but
follow-up studies are needed (6). Eosinophilic in£amma-
tion can heal spontaneously, especially if it is a result of
exposure to an allergen, which ceases.Therapy with re-
peated courses of antibiotics, coughmixtures, mucolytic
agents or bronchodilators is of little use. Prolonged eosi-
nophilic in£ammation requires treatment with an anti-
in£ammatory agent (5, 12, 30). E¡ective treatment may
have to involve inhaled steroids for 2^3 months (6).
COPD patients who exhibit eosinophilia in sputum sam-
ples experience relatively rapid declines in lung function
(31) and can also bene¢t from anti-in£ammatory therapy
(10).
We have shown that eosinophilic airway in£ammation
is fairly common in primary-care patients with pro-
longed cough, even in patients not su¡ering from asth-
ma,COPD or any other known cause of cough. Induced
sputum samples can be obtained in health centres and
sent for analysis in a central laboratory.Detection of eo-
sinophilic airway in£ammation can aid treatment deci-
sions in primary care.
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